EyePromise Targets Dry Eye Epidemic with Advanced, Clinically-Backed Tear

BLUE BELL, PA – May 18, 2026

EyePromise, a company known for its doctor-recommended eye health nutraceuticals, has stepped firmly into the crowded therapeutic drop market with the launch of Heyedrate Clinical. This new, preservative-free artificial tear is engineered to provide long-lasting relief from dry eye symptoms, a condition affecting millions of Americans. The launch introduces a European-proven technology to the U.S., aiming to address the shortcomings of conventional treatments in a market hungry for innovation.

A Growing Market Seeking Better Solutions

The market for dry eye treatments is not just large; it is expanding at a significant pace. Valued at over USD 6 billion globally in 2024, the sector is projected to surge past USD 9 billion by 2030. This growth is fueled by a confluence of modern life's challenges: an aging population more susceptible to ocular surface disease, a dramatic increase in screen time across all age groups, and environmental factors like pollution and air-conditioned spaces. For countless individuals, the result is a daily battle with discomfort, burning, and blurred vision.

Artificial tears have long been the first line of defense, dominating the over-the-counter market with a share exceeding 40%. However, patient satisfaction remains a challenge. Many conventional drops offer only fleeting relief, requiring frequent reapplication throughout the day. This has driven a clear market trend towards more sophisticated solutions. Patients and clinicians are increasingly demanding preservative-free formulations to avoid the potential for irritation from long-term use, as well as advanced ingredients that do more than just add temporary moisture.

The Science Behind Sustained Hydration

Heyedrate Clinical aims to meet this demand by moving beyond simple lubrication. Its formulation is built on a synergistic combination of povidone and Hylan A, which the company identifies as the highest molecular weight hyaluronic acid (HMWHA) available in the United States. This is the product's core scientific differentiator.

Hyaluronic acid (HA) is a well-known humectant, but scientific literature increasingly confirms that not all HA is created equal. HMWHA demonstrates superior properties for ophthalmic use compared to its lower-weight counterparts. Its complex molecular structure allows it to bind and retain significantly more water, providing a deeper level of hydration. Furthermore, its viscoelastic properties are key; it spreads smoothly across the ocular surface with each blink but quickly recovers its structure to maintain a stable, protective tear film. This mimics the behavior of natural tears, reducing friction and prolonging comfort.

Beyond lubrication, HMWHA possesses anti-inflammatory properties, a crucial benefit in managing dry eye, which is now understood to be an inflammatory condition. It also supports corneal health by promoting epithelial cell healing and nerve regeneration. Combined with povidone, another proven lubricating agent, the formulation is designed to increase "residence time"—the duration the drop remains effective on the eye's surface. This enhanced adhesion to both the corneal epithelium and the mucin layer is what promises to reduce the need for constant re-dropping. The formulation is also triple-filtered, preservative-free, and compatible with all contact lens materials, addressing several key clinician and patient concerns.

Clinical Validation and European Precedent

EyePromise is backing its scientific claims with clinical data and a history of use. The technology behind Heyedrate Clinical is not entirely new; it boasts a decade-long track record in European markets, providing a foundation of real-world evidence. For its U.S. launch, the company highlights a multicenter randomized trial that underscores the product's efficacy.

The study revealed a clinically significant 27% reduction in the daily frequency of drops required by subjects using the HMWHA formulation compared to those using their conventional artificial tears over an eight-week period. This data point directly addresses a major pain point for chronic dry eye sufferers: the burden of frequent application. Furthermore, the trial measured patient-reported outcomes using the standard Ocular Surface Disease Index (OSDI). After just four weeks, 77% of subjects using Heyedrate Clinical reported an improvement in their OSDI score, representing a 26% greater improvement versus the control group.

"Heyedrate Clinical is grounded in technology with a decade-long clinical track record in Europe," said Dr. Kimberly Friedman, OD, FAAO, Chief Medical Education Officer at EyePromise, in a statement. "Featuring povidone with the inclusion of ultra-high molecular weight hyaluronic acid, it delivers intensive, long-lasting hydration that clinically demonstrates meaningful results in patient tear film outcomes. I'm excited to offer this level of performance to patients in the United States."

A Multifaceted Strategy in a Competitive Field

The launch of Heyedrate Clinical is more than just a new product release; it represents a strategic move to solidify EyePromise's position as a comprehensive leader in ocular health. The company is intentionally positioning the new artificial tear not as a standalone solution, but as the topical relief component of a broader, multifactorial management strategy. This ecosystem includes its flagship De3 Omega Benefits, the #1 doctor-recommended nutraceutical for occasional dry eye, and Avenova Lid & Lash Cleansing Spray for ocular hygiene.

This integrated approach allows clinicians to address dry eye from multiple angles—internal nutrition, external hygiene, and now, advanced topical hydration. It's a strategy designed to build loyalty and provide a holistic care regimen that stands out in a market dominated by product-focused giants like Alcon's Systane and Allergan's Refresh. While these established brands offer a wide array of formulations, EyePromise is betting that its focus on an integrated, clinically-backed system will appeal to practitioners and patients seeking a more comprehensive and effective long-term solution.

"Heyedrate Clinical completes our comprehensive eye hydration portfolio alongside De3 and Avenova, enabling clinicians to address occasional eye dryness through a multimodal approach," noted Thu Bang, Head of Marketing at EyePromise. "Eye care professionals can trust this product because it's built on the same rigorous clinical standards that have defined EyePromise, and we're bringing European-clinically backed technology supported by multicenter trial data to the U.S. market."

With its direct-to-practitioner and patient availability online, EyePromise is ensuring broad access while leveraging its established reputation within the clinical community. The launch of Heyedrate Clinical signals a clear ambition to compete not just on brand recognition, but on scientific innovation and superior patient outcomes in the challenging landscape of dry eye care.